Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
Clinical Pharmacokinetics|August 27, 2009
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicamThorsten Lehr, Alexander Staab, Christiane Tillmann, et al.
Infectious Disease Modelling|January 8, 2026
Integrating Kolmogorov-Arnold networks with ordinary differential equations for efficient, interpretable, and robust deep learning: Epidemiology of infectious diseases as a case studyKexin Ma, Xu Lu, Nicola Luigi Bragazzi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 10, 2016
A generic viral dynamic model to systematically characterize the interaction between oncolytic virus kinetics and tumor growthMelanie I Titze, Julia Frank, Michael Ehrhardt, et al.
Plos One|May 15, 2025
Effects of an interprofessional care concept in nursing homes evaluated in the SaarPHIR project: A cluster-randomized controlled trialLisa Tönnies, Viola Zimmer, Alexandra Piotrowski, et al.
Clinical Pharmacology and Therapeutics|May 9, 2022
Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N<sup>1</sup> -Methylnicotinamide: A PBPK Modeling ApproachDenise Türk, Fabian Müller, Martin F Fromm, et al.
Clinical Pharmacokinetics|May 20, 2019
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired PatientsDaniel Moj, Hugo Maas, André Schaeftlein, et al.
Pharmaceutics|July 27, 2022
A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction ModelingLaura Maria Fuhr, Fatima Zahra Marok, Maximilian Mees, et al.
Pharmaceutics|June 27, 2020
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm NeonatesLukas Kovar, Christina Schräpel, Dominik Selzer, et al.
Pharmaceutics|August 26, 2022
Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and RisperidoneSimeon Rüdesheim, Dominik Selzer, Thomas Mürdter, et al.
Molecular Oncology|May 10, 2016
MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibitionLina S Schneider, Melanie Ulrich, Thorsten Lehr, et al.
Pageof 13